Surgery
Conditions
Interventions
Sponsors
Andriy Kirpichnikov
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: • Patients between the age 18–70 years; • Patients who have undergone elective and/or emergency abdominal surgery either laparoscopic or open.
Exclusion criteria
Exclusion criteria: • Known hypersensitivity to buprenorphine; • Delirium tremens; • Patients with severe hepatic impairment; • Patients suffering from myasthenia gravis; • Patients with head injury; • Patients with a depressed level of consciousness; • Patients with known alcohol or substance abuse; • Patients with impaired respiratory function; • Patients concurrently receiving MAOIs; • Trauma patients; • Pregnant patients; • Consent refusal.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The buprenorphine patch is a perfect pain control regimen as it has better pain control and provides better comfort in all significant assessed areas of discomfort, such as insomnia, nausea, vomiting, nightmares, sweating, itching, constipation, lack of appetite, tiredness and cognitive difficulties. For example, pain at its worst was rated on Day 2 at the level of 3,49 in the buprenorphine group versus 5,79 in the tramal group. Nausea was 1,65 in the tramal group versus 0,48 in the buprenorphine group. Constipation was 2,82 in tramal group versus 1,03 in the buprenorphine group. Vomiting was rated at the level of 0,99 on Day 2 in the tramal group versus 0,07 in the buprenorphine group. The buprenorphine patch showed significantly better results in all assessed scenarios; thus, it may be recommended for use at the DGMAH | — |
Secondary
| Measure | Time frame |
|---|---|
| The use of the buprenorphine patch showed a slight increase in costs compared to the tramal group (R7800,75 vs R7537,50) in the whole study, which is a mild difference that is greatly outweighed by significant convenience and better outcomes. | — |
Countries
South Africa
Contacts
Public ContactFaizullah Ghoor
Professor
Outcome results
None listed